Nuvation Bio Inc.

NUVB
$5.65 (- $0.16 - 2.75%)
Last updated: 2026-06-28 16:14 UTC
NUVB Metrics
Exchange
🇺🇸 NYSE XNYS
New York Stock Exchange, Inc.United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS67080N1019
CUSIP67080N101
Market Price5.65
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.5
Market Cap$3.3B
Book Value0.95
Price to Book10.011
Beta1.59
52w High9.75
52w Low1.54
Next Earnings DateN/A

Nuvation Bio Inc. trades under ticker NUVB on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US67080N1019, CUSIP 67080N101.

About the Company
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Price History